NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance ...
Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics This is a randomized, double-blind, placebo-controlled, multi-center Phase 2a dose-ranging study ...
After announcing its mRNA therapy is effective against aggressive cancer cells, HOTH stock surged over 160%. Yet, since the news, Hoth Therapeutics (Nasdaq: HOTH) is again trending in the wrong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results